INTENS Logo

 

 

 

 

INTENS: INtestinal Tissue ENgineering Solution is a 5-year EU funded project which brings together 9 international partners; leaders in the field of intestinal regenerative medicine. The overall aim of INTENS is to deliver a functional bowel reconstruction to patients with intestinal failure through an autologous tissue engineering strategy, overcoming the shortage of transplantable organs, and avoiding the need for immunosuppression. It will be achieved by identifying the best autologous cell source, the ideal scaffold, and optimum bioreactor conditions necessary to generate a functional intestine for transplantation. The aim is to generate functional intestinal tissue for clinical transplantation by 2020.

The INTENS project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No [668294]

PluriMes Logo

PluriMes is a consortium of 10 European partners have been awarded €6million by the European Commission for a research and development project focused on directing stem cells to become bone and muscle. The project combines the expertise of ten academic and two industrial partners to bring together stem cell experts, genetic engineers, developmental biologists, cell therapy pioneers, bioengineers and specialist SMEs in a cross-disciplinary collaborative effort. PluriMes is supported through the European Commission’s Framework 7 HEALTH research programme and Coordinated by Professor Austin Smith from the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute at the University of Cambridge.

PluriMes has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No [602423].

Merlin Logo

MEsenchymal stem cells to Reduce Liver INflammation (MERLIN) is a four year project that will bring leading European researchers in stem cells and liver disease together with global industrial partners to look at new ways to treat liver disease with stem cells. MERLIN will specifically focus on primary sclerosing cholangitis (PSC), an inflammatory liver disease currently without effective treatments, but will also generate new knowledge that is more widely applicable to stem cell therapy in general.

MERLIN has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No [602363].

Repair HD Logo

Repair-HD researchers are taking on the complex task of exploring cell replacement therapy in HD over the next four years. Funded under the Seventh Framework Programme (FP7), the project aims to enable efficient translation of experimental stem cell therapies to preclinical work in small and large animal models, and readiness for clinical application. Repair-HD brings together an innovative and unique combination of expertise from five academic research teams based in the United Kingdom, France and Italy, and two small-to-medium-size enterprises in the United Kingdom and Germany.  The project aims to establish all the components necessary to generate functional striatal medium spiny neurons from human pluripotent stem cells, and to bring them to ‘first-in-man’ clinical trials in HD. The program has five principal objectives over the next four years:

  • 1. Improve understanding of mechanisms of neuronal differentiation
  • 2. Develop new objective clinical assessment tools
  • 3. Improve health for HD patients
  • 4. Create innovative tools for quality control
  • 5. Reduce long-term healthcare costs

The Repair-HD project has received funding from the European Union's Seventh Framework Programme for research,
technological development and demonstration under grant agreement No [602245].

Stellar Logo

STELLAR is a research consortium consisting of European and Australian researchers interested in developing an alternative to renal replacement therapy. The STELLAR consortium will make use of newly discovered kidney mesenchymal stromal cells that have the potential to regenerate and repair damaged tissue.

STELLAR is a research consortium financed under the 7th Framework Programme of the European commission under grant agreement No [305436]. STELLAR was initiated on 1 November 2012 with a project duration of 5 years.